World Journal of Endocrine Surgery

Register      Login

VOLUME 10 , ISSUE 3 ( September-December, 2018 ) > List of Articles

CASE REPORT

Neuroblastoma in Late Adolescence: Case Report and Review of Literature

Pooja Ramakant, Chanchal Rana, Shreyamsa Manjunath, Sasi Mouli

Keywords : Adrenal tumor, Late adolescence, Neuroblastoma, Sympathetic nervous system tumors

Citation Information : Ramakant P, Rana C, Manjunath S, Mouli S. Neuroblastoma in Late Adolescence: Case Report and Review of Literature. World J Endoc Surg 2018; 10 (3):157-162.

DOI: 10.5005/jp-journals-10002-1239

License: CC BY-NC 4.0

Published Online: 01-12-2018

Copyright Statement:  Copyright © 2018 Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

Neuroblastoma is an embryonal cancer of the peripheral sympathetic nervous system. It is the most common extracranial tumor of childhood and the third most common tumor overall. Neuroblastoma arises from cells of primordial neural crest. The natural history of this disease is very heterogeneous and extends from spontaneous regression to aggressive metastatic disease. Neuroblastoma in older children is extremely rare and it carries a bad prognosis. We present a case of a 15-year-old boy with unresectable neuroblastoma who was subjected to neoadjuvant chemotherapy which rendered the tumor resectable. The case highlights importance of neoadjuvant therapy in neuroblastomas, need for multimodality involvement and therapeutic challenges faced by phycisians in successfully treating aggressive neuroblastomas.


PDF Share
  1. Maris JM, Hogarty MD, Cohn SL. “Neuroblastoma.” The Lancet, 2007;369(9579):2106-2120.
  2. Park JR, Eggert A, Caron H. Neuroblastoma: biology, prognosis, and treatment. Hematology/oncology clinics of North America. 2010 Feb 1;24(1):65-86.
  3. Parikh NS, Howard SC, Chantada G. SIOP-PODC adapted risk stratification and treatment guidelines: Recommendations for neuroblastoma in low and middle income settings. Pediatr Blood Cancer, 2015;62(8):1305-1316.
  4. Zage PE, Ater JL Neuroblastoma. In: Kliegman, Stanton, St Geme, Schor, editors. Nelson textbook of paediatrics. 20th edition; New York: Elsevier: 2016. Chapter 498, 2461-2464.
  5. Mossé YP, Deyell RJ, Berthold F, Nagakawara A, Ambros PF, Monclair T, et al. Neuroblastoma in older children, adolescents and young adults: a report from the International Neuroblastoma Risk Group project. Pediatric blood & cancer. 2014 Apr;61(4):627-635.
  6. Steliarova-Foucher E, Colombet M, Ries LA, Moreno F, Dolya A, Bray F, et al. International incidence of childhood cancer, 2001–10: a population-based registry study. The Lancet Oncology. 2017 Jun 1;18(6):719-731.
  7. Vo KT, Matthay KK, Neuhaus J, London WB, Hero B, Ambros PF, et al. Clinical, biologic, and prognostic differences on the basis of primary tumor site in neuroblastoma: a report from the international neuroblastoma risk group project. Journal of clinical oncology. 2014 Oct 1;32(28):3169-3176.
  8. Cohn SL, Pearson AD, London WB, Monclair T, Ambros PF, Brodeur GM, et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG task force report. Journal of clinical oncology. 2009 Jan 10;27(2):289-297.
  9. Irwin MS, Park JR. Neuroblastoma: paradigm for precision medicine. Pediatric Clinics of North America. 2015 Feb;62(1):225-256.
  10. Castleberry RP. Biology and treatment of neuroblastoma. Pediatric Clinics of North America. 1997 Aug;44(4):919-937.
  11. Krug P, Schleiermacher G, Michon J, Valteau-Couanet D, Brisse H, Peuchmaur M, et al. Opsoclonus–myoclonus in children associated or not with neuroblastoma. european journal of paediatric neurology. 2010 Sep 1;14(5):400-409.
  12. Han W, Wang HM. Refractory diarrhea: A paraneoplastic syndrome of neuroblastoma. World Journal of Gastroenterology: WJG. 2015 Jul 7;21(25):7929-7932.
  13. Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993 Aug;11(8):1466-1477.
  14. Brisse HJ, McCarville MB, Granata C, Krug KB, Wootton- Gorges SL, Kanegawa K, et al. Guidelines for imaging and staging of neuroblastic tumors: consensus report from the International Neuroblastoma Risk Group Project. Radiology. 2011 Oct;261(1):243-257.
  15. Monclair T, Brodeur GM, Ambros PF, Brisse HJ, Cecchetto G, Holmes K, et al. The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol. 2009 Jan 10;27(2):298-303.
  16. Cheung NK, Dyer MA. Neuroblastoma: developmental biology, cancer genomics and immunotherapy. Nature Reviews Cancer. 2013 Jun;13(6):397-411.
  17. Pinto NR, Applebaum MA, Volchenboum SL, Matthay KK, London WB, Ambros PF, et al. Advances in risk classification and treatment strategies for neuroblastoma. J. Clin. Oncol. 2015; 33: pp. 3008-3017
  18. Castel V, Villamón E, Cañete A, Navarro S, Ruiz A, Melero C, et al. Neuroblastoma in adolescents: genetic and clinical characterisation. Clinical and Translational Oncology. 2010 Jan 1;12(1):49-54.
  19. Agarwala S, Mandelia A, Bakhshi S, Srinivas M, Bajpai M, Gupta AK, et al. Neuroblastoma: Outcome over a 14 year period from a tertiary care referral centre in India. Journal of pediatric surgery. 2014 Aug 1;49(8):1280-1285.
  20. Kubota, M. The role of surgery in the treatment of neuroblastoma. Surg Today. 2010;40(6):526-532.
  21. Yanik GA, Villablanca JG, Maris JM, Weiss B, Groshen S, Marachelian A, et al. 131I-metaiodobenzylguanidine with intensive chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma. A new approaches to neuroblastoma therapy (NANT) phase II study. Biology of Blood and Marrow Transplantation. 2015 Apr 1;21(4):673-681.
  22. Kong G, Hofman MS, Murray WK, Wilson S, Wood P, Downie P, et al. Initial experience with gallium-68 DOTA-octreotate PET/CT and peptide receptor radionuclide therapy for pediatric patients with refractory metastatic neuroblastoma. Journal of pediatric hematology/oncology. 2016 Mar 1;38(2):87-96.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.